Contents

Highlights of This Issue 5543

SPECIAL FEATURES

Editorial

5545  Announcing the AACR Cancer Progress Report 2013
Jesse Potash and Kenneth C. Anderson

CCR Translations

5546  Better Performance of CARs Deprived of the PD-1 Brake
Aizea Morales-Kastresana, Sara Labiano, José I. Quetglas, and Ignacio Melero
See related article, p. 5549

5549  Coamplification and Cooperation: Toward Identifying Biologically Relevant Oncogenes
Guochang Huang and Bhuvanesh Singh
See related article, p. 5580

CCR Drug Updates

5552  Pertuzumab: Optimizing HER2 Blockade
Otto Metzger-Filho, Eric P. Winer, and Ian Krop

Molecular Pathways

5557  Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target
Elizabeth A. Grimm, Andrew G. Sikora, and Suhendan Ekmekcioglu

5564  Molecular Pathways: Human Leukocyte Antigen G (HLA-G)
Giuseppe Curigliano, Carmen Criscitiello, Lucia Gelao, and Aron Goldhirsch

Review

5572  The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
Wen Wee Ma and Manuel Hidalgo

HUMAN CANCER BIOLOGY

5580  Integrative Genomics Analysis Identifies Candidate Drivers at 3q26-29 Amplicon in Squamous Cell Carcinoma of the Lung
Jing Wang, Jun Qian, Megan D. Hoeksema, Yong Zou, Allan V. Espinosa, S.M. Jamsheed Rahaman, Bing Zhang, and Pierre P. Massion
See related article, p. 5549

5591  Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

5602  miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression
Hailin Tang, Min Deng, Yunyun Tang, Xinhua Xie, Jialin Guo, Yanan Kong, Feng Ye, Qi Su, and Xiaoming Xie

5613  Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth
Muralimohan Yeperu, Zhongzhi Wu, Anand Kulkarni, Feng Yin, Christina M. Barrett, Juhyun Kim, Mitchell S. Steiner, Duane D. Miller, James T. Dalton, and Ramesh Narayan

CANCER THERAPY: PRECLINICAL

5626  Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard, Sandra Pommey, Mark J. Smyth, and John Stagg

5636  Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark J. Smyth, Michael H. Kershaw, and Phillip K. Darcy
See related article, p. 5546
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5658</td>
<td>Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer</td>
<td>Lei Gu, Zhiyong Liao, David T. Hoang, Ayush Dagvadorj, Shilpa Gupta, Shauna Blackmon, Elsey Ellsworth, Pooja Talati, Benjamin Leiby, Michael Zinda, Costas D. Lallas, Edouard J. Trubuls, Peter McCue, Leonard Gomella, Dennis Huszar, and Marja T. Nevalainen</td>
</tr>
<tr>
<td>5658</td>
<td>CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia</td>
<td>Melinda Burgess, Devinder Gill, Richa Singhania, Catherine Cheung, Lynne Chambers, Brent A. Benyolks, Louise Smith, Peter Mollee, Nicholas Saunders, and Nigel AJ McMillan</td>
</tr>
<tr>
<td>5666</td>
<td>RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response</td>
<td>Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Thint, Tom Nevins, Kathleen Schostack, Holly Hilton, Tai-An Lin, Theresa Truit, Denise Biondi, Xiaojian Wang, Kathryn Packman, Jim Rosinski, Wendy Berkofsky-Fessler, Juan-Ping Tang, Saumya Pant, David Geho, Suzana Vega-Harring, Mark DeMarco, Hy Levitsky, and Mary Simcox</td>
</tr>
<tr>
<td>5699</td>
<td>Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinesases, Including MET</td>
<td>Wenjuan Wu, Chen Bi, Kelly M. Credille, Jason R. Manro, Victoria L. Peak, Gregory P. Donoho, Lei Yan, John A. Wijsman, S. Betty Yan, and Richard A. Walgren</td>
</tr>
<tr>
<td>5711</td>
<td>Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI</td>
<td>Erik S. Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Srijam, May Han, and Sanjiv S. Gambhir</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5733</td>
<td>REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy</td>
<td>Roberto Angioli, Stella Capriglione, Alessia Aloisi, Daniela Lauro, Ester Valentina Cafi, Nella Dugo, Roberto Monteria, Carlo De Cicco Nardone, Corrado Terranova, and Francesco Plotti</td>
</tr>
<tr>
<td>5740</td>
<td>The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis</td>
<td>Leonid L. Nikitenko, Russell Lerk, Stephen Henderson, Nischal Piller, Helen Turley, Daniele Generali, Sarah Gunningham, Helen R. Morris, Andrea Pelagatti, Margaret C.P. Rees, Adrian L. Harris, and Stephen B. Fox</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5749</td>
<td>Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAF&lt;sup&gt;V600E&lt;/sup&gt;-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression</td>
<td>Emanuela Romano, Sylvain Pradervand, Alexandra Paillausson, Johann Weber, Keith Harshman, Katja Muelethaler, Daniel Speiser, Solange Peters, Donata Rimoldi, and Olivier Michelin</td>
</tr>
</tbody>
</table>
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motzinger-Reif, and Howard L. McLeod; For the Scottish Gynaecological Clinical Trials Group

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motzinger-Reif, and Howard L. McLeod; For the Scottish Gynaecological Clinical Trials Group

Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

ABOUT THE COVER
The cover shows a section from the prostate of a patient with Gleason sum 7 prostate cancer. Duolink proximity ligation assay in the section shows strong interaction between AR and AKR1C3 (red). Nucleus was counterstained with DAPI and imaged using a fluorescent microscope. For details, see the article by Yepuru and colleagues on page 5613 of this issue.
Clinical Cancer Research

19 (20)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/20

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.